This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CSBR Champions Oncology (CSBR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrendsBuy This Stock About Champions Oncology Stock (NASDAQ:CSBR) 30 days 90 days 365 days Advanced Chart Get Champions Oncology alerts:Sign Up Key Stats Today's Range$9.00▼$9.7250-Day Range$9.11▼$10.9652-Week Range$3.60▼$11.99Volume32,633 shsAverage Volume42,600 shsMarket Capitalization$106.77 millionP/E Ratio16.59Dividend YieldN/APrice Target$12.00Consensus RatingBuy Company Overview Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ. Read More Champions Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreCSBR MarketRank™: Champions Oncology scored higher than 86% of companies evaluated by MarketBeat, and ranked 151st out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingChampions Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageChampions Oncology has received no research coverage in the past 90 days.Read more about Champions Oncology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Champions Oncology is 16.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Champions Oncology is 16.59, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.22. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.57% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Champions Oncology has recently increased by 0.63%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChampions Oncology does not currently pay a dividend.Dividend GrowthChampions Oncology does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.00 Percentage of Shares Shorted1.57% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Champions Oncology has recently increased by 0.63%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News Sentiment1.04 News Coverage This WeekMarketBeat has tracked 19 news articles for Champions Oncology this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for CSBR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Champions Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders46.98% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Champions Oncology's insider trading history. Receive CSBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CSBR Stock News HeadlinesWWE Night of Champions in Saudi Arabia hits viewership milestone5 hours ago | msn.comMark Henry Was 'Struck' By This Standout WWE Night Of Champions 2025 Match5 hours ago | msn.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.July 2 at 2:00 AM | Brownstone Research (Ad)Chelsea add more Champions League pedigree after swapping ashley Lawrence for Lyonnes' Ellie Carpenter5 hours ago | sports.yahoo.comRising WWE star’s wife is ‘proud’ after Night of Champions showingJuly 1 at 2:58 AM | msn.comNew WWE Women's Tag Team Champions Crowned, Title Match Set For EvolutionJuly 1 at 2:58 AM | msn.comWhat chaotic WWE Night of Champions finish means for John Cena and CM PunkJuly 1 at 2:58 AM | nypost.comNWWE star John Cena sends referee flying during Night of Champions matchJuly 1 at 2:58 AM | msn.comSee More Headlines CSBR Stock Analysis - Frequently Asked Questions How were Champions Oncology's earnings last quarter? Champions Oncology, Inc. (NASDAQ:CSBR) announced its earnings results on Tuesday, March, 11th. The biotechnology company reported $0.31 EPS for the quarter. The biotechnology company had revenue of $17.04 million for the quarter. Champions Oncology had a net margin of 10.97% and a trailing twelve-month return on equity of 656.65%. Read the conference call transcript. What other stocks do shareholders of Champions Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Champions Oncology investors own include Intel (INTC), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Advanced Micro Devices (AMD) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings3/11/2025Today7/02/2025Fiscal Year End4/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolNASDAQ:CSBR CIK771856 Webwww.championsoncology.com Phone(201) 808-8400Fax410-369-0390Employees143Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+55.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.06) Trailing P/E Ratio16.59 Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.28 million Net Margins10.97% Pretax Margin10.92% Return on Equity656.65% Return on Assets24.04% Debt Debt-to-Equity RatioN/A Current Ratio0.99 Quick Ratio0.99 Sales & Book Value Annual Sales$50.15 million Price / Sales2.13 Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-55.14Miscellaneous Outstanding Shares13,830,000Free Float7,331,000Market Cap$106.77 million OptionableOptionable Beta0.43 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CSBR) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Champions Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.